• To advance Development of a Unique Chronic Inflammation Pipeline
• Series A Comprises a Global Syndicate o Investors Including LSP, Pivotal bioVenture Partners and Andera Partners

Amsterdam, The Netherlands, 9 September 2021 – LSP, one of the leading life sciences and health care investors, today announced that Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, successfully completed an $83 million Series A financing by LSP and Andera Partners, who joined forces with a global syndicate of investors and existing investor, Pivotal bioVenture Partners to make this financing possible. The financing enables Evommune to continue research and development of transformative therapies through both industry and academic collaborations to treat patients with immune-mediated and chronic inflammatory diseases, such as atopic dermatitis, psoriasis and rheumatoid arthritis. In conjunction with this financing, Felice Verduyn-van Weegen, Partner at LSP, has joined the Company’s Board of Directors.

“We’re thrilled to have new backing from LSP and Andera Partners as well as other high caliber investors and continued support from Pivotal bioVenture Partners,” said Luis Peña, president and chief executive officer of Evommune. “We know there is still a considerable need for more effective and safe treatments for inflammatory diseases. Our goal is to be a significant part of the solution. This financing will allow us to advance all of the programs in our pipeline into the clinic.” 

Evommune was founded in 2020 by former senior leaders at Dermira, a wholly-owned subsidiary of Eli Lilly and Company, and industry veterans including Luis Peña, Evommune president and chief executive officer, Eugene A. Bauer, MD, chief medical officer and Hans Hofland, PhD, senior vice president, research. The company is using a proprietary skin-based discovery platform to uncover new approaches for accelerating the development of vital medicines across immunology with a focus on inflammation and dermatology. With this platform, Evommune has identified differentiated molecules that have a greater probability of being effective in treating patients with chronic inflammatory conditions.

Evommune has four investigational compounds in development which include IRAK4/TrkA, a small molecule that broadly inhibits innate inflammation; RORγt, a small molecule addressing Th17 mediated inflammation; and MRGPRX2, a small molecule to treat chronic pruritus (itch). The fourth investigational compound is a PKCtheta inhibitor which could have broad utility across a spectrum of immune-mediated, inflammatory diseases.

“We are very honored to be working with such an impressive team at Evommune, coming with decades of experience and high regard in the scientific community. Supported by Evommune’s unique tissue-based translational model, we have great confidence in their pipeline of best-in-class assets to treat chronic inflammatory diseases in patient groups where there is a high unmet need,” said Felice Verduyn-van Weegen. “I am excited to partner with this strong syndicate of investors to help the company on a successful road to and through the clinic.”